0001193125-12-059347.txt : 20120214 0001193125-12-059347.hdr.sgml : 20120214 20120214121037 ACCESSION NUMBER: 0001193125-12-059347 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120214 DATE AS OF CHANGE: 20120214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sucampo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001365216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133929237 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-83614 FILM NUMBER: 12605350 BUSINESS ADDRESS: STREET 1: 4520 EAST-WEST HIGHWAY, 3RD FLOOR CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 3019613400 MAIL ADDRESS: STREET 1: 4520 EAST-WEST HIGHWAY, 3RD FLOOR CITY: BETHESDA STATE: MD ZIP: 20814 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: S&R Technology Holdings, LLC CENTRAL INDEX KEY: 0001384384 IRS NUMBER: 522242847 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 7201 WISCONSIN AVE., SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 3019418111 MAIL ADDRESS: STREET 1: 7201 WISCONSIN AVE., SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 SC 13G/A 1 d301524dsc13ga.htm 13G/A 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

Amendment No. 3

 

 

SUCAMPO PHARMACEUTICALS, INC.

(Name of Issuer)

 

 

CLASS A COMMON STOCK

(Title of Class of Securities)

864909106

(CUSIP Number)

DECEMBER 31, 2011

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

Check the following box if a fee is being paid with this statement.    ¨

 

 

 


CUSIP No.: 864909106  

 

  (1)   

Name of Reporting Person

I.R.S. Identification No. of Above Person

 

S&R TECHNOLOGY HOLDINGS, LLC

52-2242847

  (2)  

Check the Appropriate Box if a Member of a Group

(a)  ¨        (b)  ¨

 

  (3)  

SEC Use Only

 

  (4)  

Citizenship

 

    DELAWARE

Number of

Shares

Beneficially

Owned By

Each

Reporting

Person

With

   (5)    

Sole Voting Power

 

    26,400,802(1)

   (6)   

Shared Voting Power

 

    0

   (7)   

Sole Dispositive Power

 

    26,400,802(1)

   (8)   

Shared Dispositive Power

 

    0

  (9)

 

Aggregate Amount Beneficially Owned by Each Reporting Person

 

    26,400,802(1)

(10)

 

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares    ¨

 

(11)

 

Percent of Class Represented by Amount in Row (9)

 

    63.0%

(12)

 

Type of Reporting Person

 

    OO

 

1 

Includes 26,191,050 shares of Class B Common Stock of the Issuer. Each share of Class B Common Stock is convertible at any time into one share of Class A Common Stock without further consideration. Excludes 2,485,150 shares of Class A Common Stock owned by R-Tech Ueno, Ltd. (“R-Tech”). S&R Technology Holdings, LLC is R-Tech’s largest shareholder, owning 16,370 shares, or 33.26%, of R-Tech’s capital stock as of the date of this filing. Voting and dispositive power with respect to the shares owned by R-Tech is held by its board of directors. Dr. Kuno, who, along with her husband, wholly owns S&R Technology, previously served as the chairperson of R-Tech’s board and as one of its four directors. She no longer serves in either capacity and she and her husband do not have or share voting or dispositive power with respect to these shares.

 

2


Item 1  

(a).

   Name of Issuer      
     SUCAMPO PHARMACEUTICALS, INC. (2)      
Item 1  

(b).

   Address of Issuer’s Principal Executive Offices      
    

4520 EAST-WEST HIGHWAY

SUITE 300

BETHESDA, MD 20814

     
Item 2  

(a).

   Name of Person Filing      
     S&R TECHNOLOGY HOLDINGS, LLC      
Item 2  

(b).

   Address of Principal Business Office or, if none, Residence      
    

7501 WISCONSIN AVENUE

SUITE 600

BETHESDA, MD 20814-6519

     
Item 2  

(c).

   Citizenship      
     DELAWARE      
Item 2  

(d).

   Title of Class of Securities      
     CLASS A COMMON STOCK      
Item 2  

(e).

   CUSIP No.      
     864909106      
Item 3.   If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
  NOT APPLICABLE      

 

2 

Sucampo Pharmaceuticals, Inc. (the “Issuer”) is the successor to Sucampo Pharma Americas, Inc., a Delaware corporation formerly named Sucampo Pharmaceuticals, Inc., for purposes of filings under Section 13(d) of the Securities Exchange Act of 1934, as amended, as a result of a reorganization into a holding company structure. In the reorganization the Issuer became the new parent holding company of Sucampo Pharma Americas, Inc.

 

3


Item 4.    Ownership      
   (a)    Amount beneficially owned:      
      26,400,802(3)      
   (b)    Percent of class:      
      63.0%      
   (c)    Number of shares as to which the person has:      
      (i)    Sole power to vote or to direct the vote:      
         26,400,802(3)      
      (ii)    Shared power to vote or to direct the vote:      
         0      
      (iii)    Sole power to dispose or to direct the disposition of:      
         26,400,802(3)      
      (iv)    Shared power to dispose or to direct the disposition of:      
         0      
Item 5.    Ownership of Five Percent or Less of a Class   
   NOT APPLICABLE   
Item 6.    Ownership of More than Five Percent on Behalf of Another Person      
   NOT APPLICABLE      
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
   NOT APPLICABLE
Item 8.    Identification and Classification of Members of the Group      
   NOT APPLICABLE      
Item 9.    Notice of Dissolution of Group      
   NOT APPLICABLE      
Item 10.    Certifications      
   NOT APPLICABLE      

 

3 

See footnote 1 on the cover page to this schedule.

 

4


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 13, 2012   S&R TECHNOLOGY HOLDINGS, LLC
  By:  

/s/    Kei Tolliver

  Name:   Kei Tolliver

 

5